Evidence map›Paper›PMID 34683084›Full record

ArticleJournal of personalized medicine2021

Associations of the

Natchaya Vanwong, Chonlaphat Sukasem, Weerapon Unaharassamee, Napa Jiratjintana, Chalitpon Na Nakorn, Yaowaluck Hongkaew, Apichaya Puangpetch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Natchaya VanwongDepartment of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Chonlaphat SukasemDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.ORCID 0000-0003-0033-5321
Weerapon UnaharassameeDepartment of Psychiatry, Somdet Chaopraya Institute of Psychiatry, Bangkok 10600, Thailand.
Napa JiratjintanaDepartment of Psychiatry, Somdet Chaopraya Institute of Psychiatry, Bangkok 10600, Thailand.
Chalitpon Na NakornDepartment of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla 90110, Thailand.
Yaowaluck HongkaewAdvance Research and Development Laboratory, Bumrungrad International Hospital, Bangkok 10110, Thailand.ORCID 0000-0002-4180-9696
Apichaya PuangpetchDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
Mahidol University · THSomdet Chaopraya Institute of Psychiatry · THBumrungrad International Hospital · THChulalongkorn University · THPrince of Songkla University · TH

Funding

Faculty of Allied Health Sciences, Chulalongkorn university Fund AHS-CU 61003Faculty of Medicine Ramathibodi Hospital, Mahidol University NoneGrants for Development of New Faculty Staff, Chulalongkorn University DNS 62_021_37_001_1Special Task Force for Activating Research (STAR), Rachadaphisek Somphot Fund, Chulalongkorn University STF6300237001-1
6 · The paper itself

Abstract

backgroundPatients with psychotic disorders who receive atypical antipsychotic drugs often develop metabolic abnormalities. The sterol regulatory element-binding factor 2 (SREBF2) gene and insulin-induced gene (INSIG) have important roles in lipid metabolism. A previous study indicated that risperidone stimulated both lipogenesis and cholesterogenesis through activation of SREBP2 expression and inhibition of INSIG2. The

objectiveTo investigate the association of the

methodsAll 113 psychiatric patients using risperidone were evaluated for their lipid profile and screened for obesity criteria. We genotyped the

resultsNone of the studied

conclusionsOur findings suggest that the

Indexed as

dyslipidemiaINSIG2 polymorphismobesityrisperidoneSREBF2 gene polymorphism

Identifiers

PMID34683084
PMCPMC8541118
OpenAlexW3199440900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.